• Chief Executive Officer

    Raju Mohan, PhD

    Chief Executive Officer

    Raju founded Ventyx Biosciences and has served as a member of our board of directors since the company’s inception. Prior to Ventyx, Raju founded Akarna Therapeutics, which was acquired by Allergan for up to $1.2B. In addition to Ventyx, Raju has founded Oppilan Pharma, Zomagen Biosciences and Vimalan Biosciences, all immunology-focused specialty pharmaceutical companies. From 2006 to 2011, Raju served as Vice President and head of the San Diego site for Exelixis and Vice President of Chemistry at X-Ceptor Therapeutics (acquired by Exelixis). Raju started his pharmaceutical career at Berlex Biosciences, a subsidiary of Bayer/Schering AG where he held positions of increasing responsibility. Raju is responsible for the discovery of multiple small molecule drug candidates that have entered clinical trials. He is the inventor of MINNEBRO®, an approved therapeutic for hypertension. He has published extensively in peer-reviewed journals and is an inventor on 64 issued US patents. Raju received a PhD in Chemistry from the University of Illinois and a Master’s degree from the Indian Institute of Technology.
  • Chief Business Officer

    Chris Krueger, JD, MBA

    Chief Business Officer

    Chris has served as our Chief Business Officer since the company’s inception. He was mostly recently the Chief Executive Officer of Oppilan Pharma and the Chief Business Officer of Zomagen Biosciences.

    Chris brings more than 20 years of experience in the life science industry with operational responsibility and leadership for multiple functional areas, including business development, legal affairs, finance, alliance management and operations. Chris has negotiated a broad range of equity and debt financings, strategic partnerships, acquisitions and licensing transactions.

    Previously, Chris served as an executive at Akarna Therapeutics (acquired by Allergan for up to $1.2B), Ardea Biosciences (acquired by AstraZeneca), Xencor (Nasdaq:XNCR), X-Ceptor Therapeutics (acquired by Exelixis) and Aurora Biosciences (acquired by Vertex Pharmaceuticals). Earlier in his career, he was a lawyer at Cooley LLP. Chris received a J.D. and M.B.A. in Finance from the University of Southern California and a B.A. in Economics from the University of California, San Diego.

  • Chief Scientific Officer

    John Nuss, PhD

    Chief Scientific Officer

    John brings more than 25 years of small molecule drug discovery and development experience to the company, primarily in the areas of immunology, inflammation, oncology, and metabolic disease. Prior to joining Ventyx, John was Vice President of Drug Discovery at the Ferring Research Institute where he was responsible for global drug discovery activities. John also previously served as Senior Vice President of Chemistry at Exelixis. Under his leadership, his teams have advanced more than 30 molecules into the clinic. He is the co-inventor of the approved therapeutics COMETRIQ®/CABOMETYX® and MINNEBRO®, and led the team that discovered COTELLIC®. Earlier in his career he held positions of increasing responsibility in discovery at Chiron and served as an Assistant Professor of Chemistry at the University of California, Riverside. John has more than 80 publications and 30 issued patents. He received a bachelor’s degree in chemistry from the University of Kansas, a PhD in organic chemistry from the University of Wisconsin, Madison, and was an NIH postdoctoral fellow in organic synthesis at Stanford University.

  • Chief Medical Officer

    Jörn Drappa, MD, PhD

    Chief Medical Officer

    Jörn serves as our Chief Medical Officer. Prior to joining Ventyx, he served as Executive Vice President, R&D at Horizon Therapeutics. Prior to Horizon’s acquisition of Viela Bio, he served as Head of R&D and Chief Medical Officer at Viela Bio. Prior to Viela Bio, he served as Vice President, Clinical Development at MedImmune/AstraZeneca, where he headed all clinical functions outside of oncology. Prior to MedImmune/AstraZeneca, he served as Senior Medical Director for inflammation and autoimmune diseases at Genentech. Earlier in his career, he served as a Medical Director for Amgen. Jorn received his medical and Ph.D. degrees from the University of Cologne in Germany.

  • Chief Financial Officer

    Martin D. Auster, M.D.

    Chief Financial Officer

    Marty serves as our Chief Financial Officer. Prior to joining Ventyx, he served as Managing Director, Biotechnology Analyst at Credit Suisse. Prior to Credit Suisse, he was a senior biotechnology analyst at UBS Securities. Prior to that, he served as an executive at Ascendis Pharma and United Therapeutics. Earlier in his career, he held positions in the investment banking industry, including as a Senior Biotechnology Analyst at Wachovia Securities and a Senior Analyst/Healthcare-focused Portfolio Manager at GLG Partners. He received a B.A. from the University of Michigan and an M.D. from the University of Texas Medical Branch.

Email Alerts
Contact IR
RSS Feeds